Company: ATHE
Filing Date: 2025-08-29
Form Type: 20-F
Source: 0001213900-25-082027
Chunk: 30

Company: ALTERITY THERAPEUTICS LTD
Filing Date: 2025-08-29
Form: 20-F
Item: Item 3
Chunk 30
---
Intellectual property rights do not address all potential threats to our competitive advantage.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately permit us to maintain our competitive advantage. The following examples are illustrative:

●   Others may be able to make products that are similar to ours but that are not covered by the claims of the patents that we own.
-----------------------------------------------------------------------------------------------------------------------------------

●   Others may independently develop similar or alternative technologies or otherwise circumvent any of our technologies without infringing our intellectual property rights.
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

●   We or any of our collaboration partners might not have been the first to conceive and reduce to practice the inventions covered by the patents or patent applications that we own, license or will own or license.
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

18

●   We or any of our collaboration partners might not have been the first to file patent applications covering certain of the patents or patent applications that we or they own or have obtained a license, or will own or will have obtained a license.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

●   It is possible that our pending patent applications will not result in issued patents.
------------------------------------------------------------------------------------------

●                                                                             Issued patents that we own may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors.                                                                         
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
●   Our competitors might conduct research and development activities in countries where we do not have patent rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets.

●   The patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our business.
-------------------------------------------------------------------------------------------------------------------------------------------

●   Compulsory licensing provisions of certain governments to patented technologies that are deemed necessary for the government to access.
-------------------------------------------------------------------------------------------------------------------------------------------

Changes in patent laws or patent jurisprudence could diminish the value of our patents, thereby impairing our ability to protect our products or product candidates.

As is the case with other biotechnology and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the pharmaceutical industry involves both technological and legal complexity, it is costly, time-consuming and inherently uncertain. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Depending